Salvia divinorum
Viewing r2 — May 14, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Salvia divinorum (Lamiaceae) — ska María pastora — is a perennial herb native to cloud forests in Oaxaca, Mexico. Its primary psychoactive compound, salvinorin A, is unique among hallucinogens — it contains no nitrogen atom.[1] Salvinorin A activates kappa-opioid receptors, suppressing dopamine and disrupting the circuits that sustain a coherent sense of reality.[1][2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
The Mazatec people of Oaxaca have used Salvia divinorum in healing ceremonies for centuries, ingesting fresh leaves to enter visionary states.[4][5] Western scientists described the plant in 1962; in 2002, salvinorin A was identified as a kappa-opioid agonist — a hallucinogenic mechanism independent of serotonin.[1][6] Internet sales during the 2000s spread salvia globally as a legal hallucinogen, prompting bans across dozens of US states and several countries.[4]
Subjective effects include complete loss of environmental awareness, vivid internal hallucinations, deep disorientation in space and time, and distorted body sense.[7] Smoked preparations produce a sudden, overwhelming immersion lasting under 20 minutes; traditional leaf quids yield a gentler shift over 30–90 minutes.[8][5] Dysphoria, intense fear, and brief amnesia are common at smoked doses — characteristic features of the kappa-opioid mechanism, not rare side effects.[7]
No fatalities have been directly attributed to salvinorin A, and no dependence syndrome has been described.[9][3] The primary risks are psychological — the kappa-opioid mechanism makes dysphoric, frightening experiences common, and case reports link use to lasting psychosis in psychiatrically vulnerable individuals.[10] No human pharmacokinetic data have been published, commercial extract potency labels are often inaccurate,[11] and several areas of risk remain formally unstudied.
History[edit]
Traditional and historical use
The Mazatec people of the Sierra Mazateca in Oaxaca use Salvia divinorum — known as ska María pastora — in healing ceremonies (veladas), where a curandera administers fresh leaves to enter a visionary diagnostic state.[4][5][6] Centuries of practice are commonly cited, but the earliest documented Western accounts date to the mid-20th century.citation needed
Western discovery and research
R. Gordon Wasson's expeditions first brought the plant to Western attention in the late 1930s. Botanists Epling and Játiva formally described the species in 1962 from Wasson and Hofmann's first flowering specimen.[6][12] In 2002, salvinorin A was identified as a selective κ-opioid agonist — the first non-nitrogenous hallucinogen.[1]
Modern era
Internet sales during the 1990s–2000s made S. divinorum globally available as a legal hallucinogen,[4] prompting US state bans[13] and a DEA "Drug and Chemical of Concern" listing in 2009.[13] The plant remains absent from UN drug conventions,[14] and recent research focuses on salvinorin A analogues as potential treatments for pain and addiction.[15][16]
Botanical Overview[edit]
Taxonomy and family
Salvia divinorum Epling & Játiva belongs to the genus Salvia, the largest genus in the mint family (Lamiaceae).[12] It is one of the very few Salvia species with documented psychoactive properties. The species was formally described in 1962 from the first flowering specimen collected during Wasson and Hofmann's expedition.[6]
Native range and habitat
The plant is endemic to cloud forests of the Sierra Mazateca in Oaxaca, Mexico, growing in humid, shaded ravines at roughly 300–1,800 metres elevation.citation needed It requires moist conditions and does not tolerate frost or direct sun. Wild populations are rare; the plant reproduces almost entirely through stem cuttings.citation needed
Identification
S. divinorum reaches 1–1.5 metres tall with hollow, square stems — characteristic of the mint family — and large (10–30 cm), serrated leaves. Flowers appear rarely in cultivation: white with purple calyces.citation needed Large leaf size, hollow square stems, and sprawling growth distinguish it from other salvias.
Alkaloid Profile[edit]
Dominant compound
Salvinorin A is the principal — and essentially only — psychoactive compound in Salvia divinorum. It is a neoclerodane diterpenoid, not a true alkaloid: it contains no nitrogen atom.[1] At kappa-opioid receptors, salvinorin A acts as a potent full agonist with no activity at serotonin receptors or over 50 other molecular targets tested.[1]
Binding and signalling
Salvinorin A engages kappa-opioid receptors through an unusual molecular interaction — it binds differently from conventional opioid drugs.[15] It also produces rapid receptor desensitisation, meaning the effect diminishes quickly with repeated dosing in a single session.[3] Full agonist activity at the human kappa-opioid receptor was confirmed in 2004.[17]
Minor diterpenoids and variability
Several related compounds — salvinorins B through F — are present in the plant but show no meaningful psychoactive activity. Salvinorin A concentration varies across plants and growing conditions. Commercial extracts show substantial inaccuracy in potency labelling — measured salvinorin A content frequently deviates from what is stated on the product.[11]
Neuroscience[edit]
Where it acts
Salvinorin A selectively activates kappa-opioid receptors with no activity at serotonin receptors.[1] A human study confirmed this: naltrexone fully blocked salvinorin A's effects while serotonin-receptor blockade did not.[18] This suppresses dopamine in reward circuits[2] and disrupts cortical networks sustaining a sense of self[3] — producing hallucination and dissociation without euphoria.
What it changes
Activating kappa-opioid receptors engages the brain's stress-response system, explaining the characteristically aversive quality of the experience.[19][3] Dopamine suppression in reward circuits removes the pull toward repeated use. Measurable stress-hormone rises — cortisol and prolactin — are documented in humans at psychoactive doses.[20]
- No human pharmacokinetic data with plasma sampling exist for any route of administration.
- The mechanism by which the traditional quid produces effects via buccal absorption — while a controlled sublingual liquid formulation did not[21] — remains unresolved.
- No neuroimaging studies of salvinorin A in humans have been published.
Subjective Effects[edit]
The Salvia divinorum experience is unlike any other hallucinogen. Smoked preparations produce sudden total immersion — loss of environmental awareness, vivid internal hallucinations, and profound disorientation in space and time.[7] The traditional leaf quid yields something milder: light-headedness, altered body sense, and detachment from self without full hallucinatory breakthrough.[5]
Pharmacologically, the experience sits in its own category — neither the warm connectivity of serotonergic psychedelics nor the anaesthetic numbness of ketamine.[1][3] Dysphoria is the default emotional tone. Set and setting exert unusually strong influence on whether an experience moves toward fear or tolerable strangeness.[22]
Effect Grid
The full dissociative-hallucinogenic experience. Vivid internal hallucinations dominate — immersive scenario experiences, entity contact, and revisiting of childhood memories are frequently reported. Spatial disorientation is pronounced, and awareness of the physical environment may be lost entirely. Depersonalisation and derealisation are intense. Temporal disorientation distorts the perceived passage of time.
Motor control impairment is severe — users are typically unable to stand or walk safely. Bodily dissociation, body schema distortion, vestibular distortion, and sensations of being pulled or compressed are common. Dysphoria is more frequently reported than euphoria. Amnesia for portions of the experience is typical.
When smoked, the full experience lasts approximately 15–20 minutes with onset and peak coinciding at roughly 2 minutes. Post-acute cognitive fatigue and mild confusion may persist for hours. This is the tier described in most controlled human studies (Johnson 2011, MacLean 2013).
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Vestibular distortion · Visual morphing · Visual drifting · Color alteration · Geometry · Visual acuity suppression · Visual melting · Auditory suppression · Brightness alteration · Visual haze / noise · Auditory distortion · Environmental patterning · Synesthesia · Visual breathing · Visual magnification · Internal hallucinations · External hallucinations · Object transformations · Perspective hallucinations · Visual processing suppression · Object activation · Visual scenery slicing · Visual flipping · Auditory hallucinations
Color alteration · Geometry · Visual acuity suppression · Visual melting · Auditory suppression · Brightness alteration · Visual haze / noise · Auditory distortion · Environmental patterning · Synesthesia · Visual breathing · Visual magnification · Internal hallucinations · External hallucinations · Object transformations · Perspective hallucinations · Visual processing suppression · Object activation · Visual scenery slicing · Visual flipping · Auditory hallucinations
Pupil constriction · Physical fatigue · Spontaneous body sensations · Bodily heaviness · Laughter fits · Muscle relaxation · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vibrations / buzzing · Nausea · Vomiting · Bodily dissociation · Tactile hallucination
Laughter fits · Muscle relaxation · Nystagmus (eye wobbles) · Tingling / electric sensations · Trembling · Vibrations / buzzing · Nausea · Vomiting · Bodily dissociation · Tactile hallucination
Thought disorganization · Focus suppression · Information processing suppression · Memory suppression · Novelty enhancement · Analysis suppression · Cognitive dysphoria · Language suppression · Cognitive fatigue · Motivation suppression · Thought loops · Delirium · Delusions
Memory suppression · Novelty enhancement · Analysis suppression · Cognitive dysphoria · Language suppression · Cognitive fatigue · Motivation suppression · Thought loops · Delusions
Euphoria
Automaticity · Sociability suppression · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Ego dissolution · Identity alteration
Existential realization · Noetic insight · Transpersonal feelings · Voidness · Death-rebirth sequence · Near-death experience
Death-rebirth sequence · Near-death experience
Timeline · by preparation
Preparations[edit]
Fresh-leaf quid (buccal)
Fresh-leaf quid is the traditional Mazatec preparation. Fresh leaves are held in the mouth, with juice absorbed through the cheek and under the tongue.[5] Onset: 10–20 minutes to full effect. Duration: 30–90 minutes.[5] The experience is milder than smoked preparations — light-headedness, altered body sense, and mild imagery without full hallucinatory breakthrough. Requires fresh plant material.
Dried leaf (smoked)
Dried leaf — plain, non-enhanced — is smoked in a pipe or water pipe. Onset within approximately 2 minutes; effects resolve within 15–20 minutes.[8] Even without concentration, plain leaf at higher amounts can produce complete dissociation from the physical environment. Potency varies by plant source, drying method, and storage.
Concentrated extract (smoked or vaporised)
Concentrated extracts are sold with strength multipliers (5×, 10×, 20×, 60×+). These are most associated with overwhelming experiences and adverse psychological reactions. Labelled potency frequently does not reflect actual salvinorin A content.[11] Onset and duration mirror plain leaf — roughly 2 minutes onset, 15–20 minutes duration — but intensity at equivalent mass is dramatically higher.
Water infusion (oral)
Water infusion — crushed fresh leaves mixed with cold water — is a documented traditional preparation.[5] Effects are mild and brief. Rarely encountered outside traditional Mazatec contexts.
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
No human fatalities have been directly attributed to salvinorin A.[9][23] Controlled human studies found no significant changes in heart rate or blood pressure at doses of 0.375–21 μg/kg inhaled.[8]
Animal studies indicate salvinorin A impairs long-term memory at high doses — an effect blocked by kappa-opioid receptor antagonists, confirming the mechanism.[24] Brief amnesia during the acute experience is reported in human studies.[7]
Commercial S. divinorum products carry labelling accuracy concerns — measured salvinorin A content deviates substantially from labelled potency.[11] No published surveillance of pesticide residues, heavy metals, or microbial contamination in commercial products exists.
safety citation needed The absence of contaminant surveillance data does not indicate absence of contamination — it reflects a gap in the published evidence base.
Psychological Risks
Intense fear, panic, and extreme disorientation are common at typical smoked doses, particularly with concentrated extracts or in uncontrolled settings.[22] Dysphoria is more frequently reported than euphoria.[5] Complete loss of environmental awareness is the primary acute risk — individuals may fall, contact hazards, or injure themselves without recognising danger.
Case reports have linked S. divinorum use to persistent psychotic episodes in individuals with possible pre-existing psychiatric vulnerability.[10] One case involved a psychotic episode resistant to two medications before resolving with a third.[25] Multiple reviews flag elevated psychiatric risk in adolescents and those with underlying psychotic conditions.[4][26]
The causal relationship between S. divinorum and persisting psychosis is not established — all published cases involve individuals with potential pre-existing vulnerability, and no prospective psychiatric outcome data exist.
Tolerance and Dependence
Rapid loss of effect with repeated dosing within a single session (tachyphylaxis) is commonly reported.[22] No dependence syndrome has been described in the clinical literature.[26] The aversive experience and dopamine suppression in reward circuits explain the substance's low abuse potential.[3][2]
Over 52% of surveyed users reduced or stopped use within 12 months, most citing dislike of effects or loss of interest.[4] No withdrawal has been described. Multiple reviews conclude salvinorin A has low abuse potential.[3][19]
Drug Interactions
Salvinorin A is processed by liver enzymes CYP2D6, CYP1A1, CYP2E1, and CYP2C18, with an additional processing pathway (UGT2B7); it is also a P-glycoprotein substrate.[27] Inhibitors of CYP2D6 (fluoxetine, paroxetine, quinidine) or CYP2E1 (disulfiram) could raise salvinorin A levels and prolong effects.
- CNS depressants (opioids, benzodiazepines, alcohol, cannabis): Additive CNS depression, disorientation, and impaired motor control are theoretically possible.safety citation needed
- Lithium: seizure risk has been reported anecdotally with lithium in combination with psychedelics. No specific case report with salvinorin A exists.safety citation needed
- MAOIs and SSRIs: Theoretical pharmacodynamic concern given κ-opioid and SERT interactions. No clinical case reports.safety citation needed
Contraindications
Absolute:
- Personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features) — case reports document persistent psychotic episodes in individuals with possible pre-existing vulnerability[10][25]
Relative:
- Adolescence — elevated risk flagged in multiple reviews; the developing brain may be especially sensitive to kappa-opioid-mediated dopamine suppression[4][26]
- Pregnancy and breastfeeding — no published safety data existsafety citation needed
- Hepatic impairment — enzyme involvement in salvinorin A metabolism suggests possible altered clearance in liver disease[27]
- Concurrent use of CYP2D6 or CYP2E1 inhibitors — theoretical risk of increased salvinorin A exposure
- Unsupervised settings or environments with fall risk — motor control impairment and complete environmental unawareness at typical smoked doses create physical injury risk[22]
Standard urine drug screens do not detect salvinorin A. Detection requires a specialised laboratory test (LC-MS/MS).[28]
Harm Reduction[edit]
Forms & Identification
Salvia divinorum products range from plain dried leaf to highly concentrated extracts (5×, 10×, 20×, and higher). Labelled potency does not reliably correspond to measured salvinorin A content.[11] No standard testing programme or Certificate of Analysis requirement exists for these products.
Lower-strength preparations (plain leaf or 5×) offer more predictable dosing than high-concentration extracts. No reagent testing kit reliably quantifies salvinorin A in home settings.
Guidelines
Practical Guidance
- Begin with plain dried leaf before attempting any concentrated extract
- Use the smallest amount possible for a first experience — salvinorin A is active at microgram doses
- Ensure a sober sitter is present throughout the experience and for at least 15 minutes after apparent offset
- Sit or lie down before administration — never stand during onset
- Remove all fire sources, sharp objects, and fall hazards from the immediate environment
- Do not drive or operate machinery for at least one hour after effects resolve
- Do not redose within the same session — tachyphylaxis makes repeated dosing unpredictable
- Avoid use in unfamiliar environments, at social gatherings, or in any setting where uncontrolled movement poses a risk
- Avoid combining with CNS depressants, alcohol, or other psychoactive substances
Set & Setting
Set and setting exert unusually strong influence on the S. divinorum experience.[22] The substance's capacity to obliterate environmental awareness makes the physical setting critical.
A quiet, dimly lit indoor space with soft surfaces and no sharp edges or hazards is essential. A sober, trusted sitter is not optional at any dose above threshold. The sitter's role is physical safety — preventing falls, contact with flame, and wandering into dangerous areas.
The sitter should not attempt to interact with or redirect the experience unless physical safety is at risk.
Aftercare & integration.
Post-Experience Processing
The intensity of the S. divinorum experience frequently leaves individuals shaken or emotionally unsettled even after acute effects resolve. Allow 30–60 minutes of quiet recovery before returning to normal activities.
Amnesia for portions of the experience is common.[7] Writing or recording impressions shortly after can help with processing. Persistent dysphoria, anxiety, or a sense of unreality lasting more than 24 hours warrants professional consultation.
Hydration and a light meal after the experience may ease physical discomfort. Avoid further psychoactive substance use for the remainder of the day.
Recovery & Support
Cessation and Support Resources
Compulsive S. divinorum use is rare due to the substance's aversive character and low reinforcement potential.[3] Any pattern of use that causes distress or impairment warrants professional attention.
If S. divinorum use has triggered or worsened psychiatric symptoms — particularly psychosis, persistent anxiety, or depersonalisation — seek evaluation from a mental health professional experienced with substance-related presentations.
- SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7)
- Crisis Text Line: Text HOME to 741741
- Emergency services: Call 911 (US) or local emergency number for acute psychiatric crisis
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency
- Complete unresponsiveness lasting more than 5 minutes after smoking
- Attempts to stand, walk, or run while unaware of physical surroundings
- Severe panic with agitation that does not begin to resolve within 10–15 minutes
- Self-harm attempts or violent behaviour
- Psychotic symptoms (paranoia, delusions, disorganised speech) persisting beyond 30 minutes after smoking
Immediate steps
- Ensure the person is in a safe position (seated or lying on their side) and cannot fall or contact hazards
- Speak calmly and reassuringly — do not physically restrain unless they are in immediate danger
- If panic is present, reassure them the effects are temporary and will pass within minutes
- Call emergency services if psychotic symptoms persist beyond 30 minutes, if there is any injury, or if the person remains unresponsive
What to tell the dispatcher
State the substance (Salvia divinorum or salvinorin A), the approximate amount and preparation used, time of administration, and current symptoms. Good Samaritan laws exist in many jurisdictions and provide legal protection for reporting drug-related emergencies.
No pharmacological reversal agent for salvinorin A is available outside clinical settings. Naltrexone blocks κ-opioid effects but is not carried by first responders and is not indicated for acute field management.
Legal Status[edit]
Salvia divinorum and salvinorin A are not listed under any UN international drug control convention.[14][29] This has produced a fragmented global legal landscape. In the United States, the plant is not federally scheduled — the DEA lists it as a "Drug and Chemical of Concern" but has not pursued scheduling[13] — but approximately 27 states have banned or restricted it. Canada added it to Schedule IV in 2017.[29] The United Kingdom banned it under the Psychoactive Substances Act 2016.[29] Australia places it on Schedule 9 — the most restrictive category — including live plants.[29] Germany, Japan, and numerous EU member states have enacted domestic controls.[14][29] Because salvinorin A contains no nitrogen atom, it falls outside the structural definitions used by many drug structural analog laws — jurisdictions that control it have done so by specifically naming the plant or compound.
Legal status changes frequently. This overview reflects the status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information.
references
- [1]
- [2] ^abcCarlezon WA, Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats — Journal of Pharmacology and Experimental Therapeutics PMID:16223871
- [3]
- [4]
- [5]
- [6] ^abcdCasselman I, Nock CJ, Wohlmuth H, Weatherby RP, Heinrich M (2014) From local to global-fifty years of research on Salvia divinorum. — Journal of ethnopharmacology doi:10.1016/j.jep.2013.11.032